• Je něco špatně v tomto záznamu ?

Novel substrate-based inhibitors of human glutamate carboxypeptidase II with enhanced lipophilicity

A. Plechanovová, Y. Byun, G. Alquicer, L. Skultétyová, P. Mlčochová, A. Němcová, HJ. Kim, M. Navrátil, R. Mease, J. Lubkowski, M. Pomper, J. Konvalinka, L. Rulíšek, C. Bařinka,

. 2011 ; 54 (21) : 7535-7546. [pub] 20111011

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, Research Support, N.I.H., Extramural, Research Support, N.I.H., Intramural, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc12022404

Virtually all low molecular weight inhibitors of human glutamate carboxypeptidase II (GCPII) are highly polar compounds that have limited use in settings where more lipophilic molecules are desired. Here we report the identification and characterization of GCPII inhibitors with enhanced liphophilicity that are derived from a series of newly identified dipeptidic GCPII substrates featuring nonpolar aliphatic side chains at the C-terminus. To analyze the interactions governing the substrate recognition by GCPII, we determined crystal structures of the inactive GCPII(E424A) mutant in complex with selected dipeptides and complemented the structural data with quantum mechanics/molecular mechanics calculations. Results reveal the importance of nonpolar interactions governing GCPII affinity toward novel substrates as well as formerly unnoticed plasticity of the S1' specificity pocket. On the basis of those data, we designed, synthesized, and evaluated a series of novel GCPII inhibitors with enhanced lipophilicity, with the best candidates having low nanomolar inhibition constants and clogD > -0.3. Our findings offer new insights into the design of more lipophilic inhibitors targeting GCPII.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc12022404
003      
CZ-PrNML
005      
20170410101408.0
007      
ta
008      
120806s2011 xxu f 000 0#eng||
009      
AR
024    7_
$a 10.1021/jm200807m $2 doi
035    __
$a (PubMed)21923190
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Plechanovová, Anna $u Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic , Flemingovo náměstí, Praha 6, Czech Republic.
245    10
$a Novel substrate-based inhibitors of human glutamate carboxypeptidase II with enhanced lipophilicity / $c A. Plechanovová, Y. Byun, G. Alquicer, L. Skultétyová, P. Mlčochová, A. Němcová, HJ. Kim, M. Navrátil, R. Mease, J. Lubkowski, M. Pomper, J. Konvalinka, L. Rulíšek, C. Bařinka,
520    9_
$a Virtually all low molecular weight inhibitors of human glutamate carboxypeptidase II (GCPII) are highly polar compounds that have limited use in settings where more lipophilic molecules are desired. Here we report the identification and characterization of GCPII inhibitors with enhanced liphophilicity that are derived from a series of newly identified dipeptidic GCPII substrates featuring nonpolar aliphatic side chains at the C-terminus. To analyze the interactions governing the substrate recognition by GCPII, we determined crystal structures of the inactive GCPII(E424A) mutant in complex with selected dipeptides and complemented the structural data with quantum mechanics/molecular mechanics calculations. Results reveal the importance of nonpolar interactions governing GCPII affinity toward novel substrates as well as formerly unnoticed plasticity of the S1' specificity pocket. On the basis of those data, we designed, synthesized, and evaluated a series of novel GCPII inhibitors with enhanced lipophilicity, with the best candidates having low nanomolar inhibition constants and clogD > -0.3. Our findings offer new insights into the design of more lipophilic inhibitors targeting GCPII.
650    _2
$a antigeny povrchové $x genetika $7 D000954
650    _2
$a vazebná místa $7 D001665
650    _2
$a krystalografie rentgenová $7 D018360
650    _2
$a dipeptidy $x chemická syntéza $x chemie $x farmakologie $7 D004151
650    _2
$a glutamátkarboxypeptidasa II $x antagonisté a inhibitory $x genetika $7 D043425
650    _2
$a lidé $7 D006801
650    _2
$a kinetika $7 D007700
650    _2
$a ligandy $7 D008024
650    _2
$a molekulární modely $7 D008958
650    _2
$a mutageneze cílená $7 D016297
650    _2
$a konformace proteinů $7 D011487
650    _2
$a kvantová teorie $7 D011789
650    _2
$a vztahy mezi strukturou a aktivitou $7 D013329
650    _2
$a substrátová specifita $7 D013379
650    _2
$a termodynamika $7 D013816
655    _2
$a časopisecké články $7 D016428
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
655    _2
$a Research Support, N.I.H., Intramural $7 D052060
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Byun, Youngjoo
700    1_
$a Alquicer, Glenda $7 gn_A_00004790
700    1_
$a Skultétyová, L'ubica
700    1_
$a Mlčochová, Petra
700    1_
$a Němcová, Adriana
700    1_
$a Kim, Hyung-Joon
700    1_
$a Navrátil, Michal
700    1_
$a Mease, Ronnie
700    1_
$a Lubkowski, Jacek
700    1_
$a Pomper, Martin
700    1_
$a Konvalinka, Jan
700    1_
$a Rulíšek, Lubomír
700    1_
$a Bařinka, Cyril
773    0_
$w MED00010049 $t Journal of medicinal chemistry $x 1520-4804 $g Roč. 54, č. 21 (2011), s. 7535-7546
856    41
$u https://pubmed.ncbi.nlm.nih.gov/21923190 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y m $z 0
990    __
$a 20120806 $b ABA008
991    __
$a 20170410101705 $b ABA008
999    __
$a ok $b bmc $g 944317 $s 779701
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2011 $b 54 $c 21 $d 7535-7546 $e 20111011 $i 1520-4804 $m Journal of medicinal chemistry $n J Med Chem $x MED00010049
LZP    __
$a Pubmed-20120806/12/01

Najít záznam

Citační ukazatele

Nahrávání dat ...

    Možnosti archivace